Prolonged cold ischemic times and less donor-recipient histocompatibility accelerate graft vascular disease

L S C Czer1, A V Wong, H Soukiasian

  • 1Division of Cardiology, Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA. Lawrence.czer@cshs.org

Transplantation Proceedings
|December 17, 2011
PubMed

Insights

Longer cold storage and reduced donor-recipient compatibility worsen graft vascular disease (GVD) after heart transplants. Greater histocompatibility can lessen the negative impact of extended cold ischemic preservation time (CIPT) on GVD.

Area of Science:

  • Transplantation immunology
  • Vascular biology
  • Organ preservation

Background:

  • Graft atherosclerosis, or graft vascular disease (GVD), limits long-term cardiac transplant success and is the primary cause of late allograft failure.
  • Understanding factors influencing GVD is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the impact of cold ischemic preservation time (CIPT) and donor-recipient histocompatibility on GVD development.
  • To utilize a rat heterotopic cardiac transplantation model to assess these factors.

Main Methods:

  • Three rat donor-recipient strain combinations with varying degrees of histocompatibility (ACI-Lewis, Lewis-F344, Lewis-Lewis) were used.
  • Grafts underwent varying CIPT durations (0, 4, and 24 hours).
  • Graft atherosclerosis was quantified by intimal area ratio (IAR), intimal thickness score (ITS), and rejection score (RS) at 90 days.

Main Results:

  • Longer CIPT (24 vs 0 hours) significantly increased rejection scores in Lewis-Lewis and Lewis-F344 groups.
  • The Lewis-F344 group showed significantly higher IAR, ITS, and RS with longer CIPT.
  • ACI-Lewis allografts exhibited high GVD across all CIPT durations, with significantly higher IAR, ITS, and RS compared to Lewis-Lewis and Lewis-F344 groups at 0 hours CIPT.

Conclusions:

  • Both prolonged CIPT and reduced donor-recipient histocompatibility are associated with increased GVD.
  • Major histocompatibility complex (MHC) mismatches, as seen in ACI-Lewis grafts, exacerbated GVD.
  • Non-MHC antigen differences also contributed to GVD, though greater histocompatibility in Lewis-Lewis isografts mitigated the effects of longer ischemic times.
Abstract